Expanded Access for Nevirapine and Delavirdine Makers of the non-nucleoside reverse transcriptase inhibitor delavirdine and nevirapine (Viramune) have filed for regulatory approval and announced temporary programs for early access to the drugs for HIV-infected individuals with CD4 cell counts <…
Clinton, Shalala, Fleming Host Gathering of AIDS Advocates, Care Givers and People Living with HIV at Day-Long Conference Election Year Sleight of Hand? On December 6, 1995, the White House held a one-day conference on HIV and AIDS. TAG Policy…
Amino Acid Substitutions Conferring Reduced Sensitivity to Selected Protease Inhibitors saquinavir (Invirase) 48 90 ritonavir (Norvir) 36 46 54 71 82 84 indinavir (Crixivan) 36 46 54 71 82 84 90 nelfinavir (Viracept) 48 84 90 VX-478 46 84…
Confab's Clarion Call: "Get It Down and Keep It Down," with Hints--And Only Hints--Of How To Get There Heyday for RNA At long last, the data nearly justifies the hype! Activists, doctors and researchers were almost giddy with excitement following…
Message from CPCRA 007 and other combination studies "You're only naïve once." More ubiquitous than even the unimaginative Steelers-Cowboys Superbowl Sunday banter was the sight of euphoric virologists high-fiving each other in the conference corridors with hearty cheers of "It's…
ACTG Oncology Committee Finds New Home at National Cancer Institute, But Funding Is Woefully Inadequate Six Studies Slated After eight, long, hard years of work with the ACTG and Division of AIDS (DAIDS), the Oncology Committee was finally pushed out…
AIDS Therapeutics Omitted from the NY State ADAP Formulary as of 1/96: Chemical name Trade name saquinavir Invirase alpha interferon Intron A, Roferon erythropoietin (EPO) Procrit, Epogen G-CSF Neupogen GM-CSF Leukine IVIG for adults Gamimune, Sandoglobulin dronabinol Marinol megestrol…
Federal Budget Shutdown and Flood of New Approvals Combine to Threaten Access to FDA-Approved AIDS Drugs Bankrupt ADAPs In the fall of 1995, the U.S. Food and Drug Administration (FDA) approved several expensive new AIDS drugs, including oral ganciclovir for…
When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary A Question of Patient Management The most important CMV data to come out of the recent ICAAC conference was the late-breaking presentation of CPCRA…
How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals Grave disservice to the public health The FDA's Antiviral Drug Products Advisory Committee met on November 6-8 in a marathon session to…